- •Most referrals for advanced heart failure (AHF) therapies originate from heart failure (HF) cardiologists.
- •Worsening HF, inotrope dependence, hospitalization, and shock often prompt referral.
- •Many patients are too ill or have psychosocial limitations precluding AHF therapies.
- •Patients referred by HF cardiologists were more likely to receive AHF therapy.
Therapies for advanced heart failure (AHF) improve the likelihood of survival in a growing population of patients with stage D heart failure (HF). Successful implementation of these therapies is dependent upon timely and appropriate referrals to AHF centers.
We performed a retrospective analysis of patients referred to 9 AHF centers for evaluation for AHF therapies. Patients’ demographics, referring providers’ characteristics, referral circumstances, and evaluation outcomes were collected.
The majority of referrals (n = 515) were male (73.4%), and a majority of those were in the advanced state of the disease: very low left ventricular ejection fraction (<20% in 51.5%); 59.4% inpatient; and high risk Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profiles (74.5% profile 1–3). HF cardiologists (49.1%) were the most common originating referral source; the least common (4.9%) were electrophysiologists. Common clinical triggers for referral included worsening HF (30.0%), inotrope dependence (19.6%), hospitalization (19.4%), and cardiogenic shock (17.8%). Most commonly, AHF therapies were not offered because patients were too sick (38.0%–45.1%) or for psychosocial reasons (20.3%–28.6%). Compared to non-HF cardiologists, patients referred by HF cardiologists were offered an AHF therapy more often (66.8% vs 58.4%, P = 0.0489). Of those not offered any AHF therapy, 28.4% received home inotropic therapy, and 14.5% were referred to hospice.
In this multicenter review of AHF referrals, HF cardiologists referred the most patients despite being a relatively small proportion of the overall clinician population. Late referral was prevalent in this high-risk patient population and correlates with worsened outcomes, suggesting a significant need for broad clinician education regarding the benefits, triggers and appropriate timing of referral to AHF centers for optimal patient outcomes.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Cardiac Failure
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.J Am Coll Cardiol. 2018; 71: 201-230
- Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology.Eur J Heart Fail. 2018; 20: 1505-1535
- Defining advanced heart failure: a systematic review of criteria used in clinical trials.J Card Fail. 2016; 22: 569-577
- Prevalence, neurohormonal correlates, and prognosis of heart failure stages in the community.JACC Heart Fail. 2016; 4: 808-815
- Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee.J Card Fail. 2015; 21: 519-534
- Focusing on referral rather than selection for advanced heart failure therapies.Card Fail Rev. 2019; 5: 24-26
- Decision making in advanced heart failure: a scientific statement from the American Heart Association.Circulation. 2012; 125: 1928-1952
- Patient selection for advanced heart failure therapy referral.Crit Pathw Cardiol. 2014; 13: 1-5
- Considerations for referral: what happens to patients after being turned down for left ventricular assist device therapy.J Card Fail. 2019; 6: 300-307https://doi.org/10.1016/j.cardfail.2019.10.009
- Patient selection for ventricular assist devices: a moving target.J Am Coll Cardiol. 2013; 61: 1209-1221
- High early event rates in patients with questionable eligibility for advanced heart failure therapies: results from the Medical Arm of Mechanically Assisted Circulatory Support (Medamacs) registry.J Heart Lung Transplant. 2016; 35: 722-730
- Outcomes with ambulatory advanced heart failure from the Medical Arm of Mechanically Assisted Circulatory Support (MedaMACS) Registry.J Heart Lung Transplant. 2019; 38: 408-417
- Eighth annual INTERMACS report: special focus on framing the impact of adverse events.J Heart Lung Transplant. 2017; 36: 1080-1086
- Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland.Eur J Heart Fail. 2017; 19: 1095-1104
- "I Need Help": a mnemonic to aid timely referral in advanced heart failure.J Heart Lung Transplant. 2017; 36: 593-594
- Psychosocial evaluation of candidates for heart transplant and ventricular assist devices: beyond the current consensus.Circ Heart Fail. 2019; 12e006058
- Clinical characteristics and outcomes of intravenous inotropic therapy in advanced heart failure.Circ Heart Fail. 2015; 8: 880-886
- Palliative care in heart failure: the PAL-HF randomized, controlled clinical trial.J Am Coll Cardiol. 2017; 70: 331-341
Published online: June 15, 2021
Accepted: May 19, 2021
Received in revised form: May 19, 2021
Received: September 11, 2020
© 2021 Elsevier Inc. All rights reserved.